|
Match
|
Document |
Document Title |
|
|
US20090291902 |
INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
The present invention relates to compounds of formula I:
or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus...
|
|
|
US20090291901 |
Control of radiation injury
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles,...
|
|
|
US20090286747 |
MNTF PEPTIDE COMPOSITIONS AND METHODS OF USE
The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides...
|
|
|
US20090285786 |
METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH
The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease...
|
|
|
US20090285774 |
Hepatitis C Virus Inhibitors
Hepatitis C virus inhibitors having the general formula
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
|
|
|
US20090281042 |
COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION OF VIRUSES
An isolated peptide is provided. The isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,...
|
|
|
US20090281033 |
Control of radiation injury
The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles,...
|
|
|
US20090280165 |
COMPOUNDS THAT BIND ALPHA5BETA1 INTEGRIN AND METHODS OF USE
The present invention provides biologically active compounds that bind an αsβi integrin. Also included in the present invention are methods for using such biologically active compounds.
|
|
|
US20090275500 |
PEPTIDE-CONTAINING FOOD INTAKE REGULATOR
A safe and widely-applicable food intake regulator can be provided by using at least one peptide selected from the group consisting of a fish or mammalian melanin-concentrating hormone (MCH) and...
|
|
|
US20090274752 |
COSMETIC AND DERMATOLOGICAL FORMULATIONS OF MNTF PEPTIDES
The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.
|
|
|
US20090274737 |
IMPLANT COMPRISING A SURFACE OF REDUCED THROMBOGENICITY
An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of Θ, where Θ≦80°. Also disclosed is a method for...
|
|
|
US20090274648 |
HEPATITIS C VIRUS INHIBITORS
Hepatitis C virus inhibitors having the general formula
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
|
|
|
US20090270337 |
Composition Comprising Carbohydrates and Peptides which Comprise Tryptophan
An edible composition comprising peptides rich in tryptophan, which edible composition further comprises a rapidly available glucose composition and a slowly available glucose composition.
|
|
|
US20090270336 |
Piperazine derivatives
This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that...
|
|
|
US20090269331 |
CASPASE-8 AND INFLAMMATION, INFECTION AND WOUND HEALING
The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healing
|
|
|
US20090264373 |
SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P 450 CYP inhibition and low...
|
|
|
US20090264369 |
METHODS FOR REDUCING CD36 EXPRESSION
The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net...
|
|
|
US20090263522 |
Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an...
|
|
|
US20090263472 |
ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES
Endothelin receptor antagonist nitroderivatives of general formula (I):
having an improved pharmacological activity compared with their parent compounds. They can be employed for treating or...
|
|
|
US20090263374 |
METHOD OF PREVENTING AND TREATING BRAIN INFARCTION
The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well...
|
|
|
US20090258834 |
Plasma protein-binding ligands
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10...
|
|
|
US20090257978 |
Antiviral coumpounds
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and...
|
|
|
US20090253641 |
METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE
The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic...
|
|
|
US20090253640 |
INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE
Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R 1 -X-A-B(R 2...
|
|
|
US20090247468 |
PHARMACEUTICAL COMPOSITIONS
Methods of spray drying are described.
|
|
|
US20090247466 |
NEUROPROTECTIVE INTEGRIN-BINDING PEPTIDE AND ANGIOPOIETIN-1 TREATMENTS
The present invention provides therapeutic compositions, kits and methods for treating nervous system injury in a mammal. Certain methods include administering to a mammal in need of such therapy...
|
|
|
US20090246251 |
COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE
The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second...
|
|
|
US20090246250 |
COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE
The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second...
|
|
|
US20090246217 |
Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity
In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including...
|
|
|
US20090239809 |
Process For Preparing Peptide Products For Promoting Cholecystokinin Secretion And Use Of The Peptide Products
A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide...
|
|
|
US20090239808 |
CALCIUM RECEPTOR ACTIVATOR
A calcium receptor activator and compositions containing at least one of the following: γ-Glu-Cys-Gly, γ-Glu-Cys(SNO)-Gly, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val,...
|
|
|
US20090239807 |
Methods and kits for diagnosing and/or assessing severity and treating gaucher disease
Methods and kits for treating Gaucher disease are provided. The methods are based on using agents capable of inhibiting proteasomal degradation of glucocerebrosidase and/or elevating a level of...
|
|
|
US20090238895 |
NUTRITIONAL AND/OR PHARMACEUTICAL PREPARATION FOR USE IN PROPHYLAXIS AND TREATMENT OF DISTURBANCES IN MICROELEMENTS ABSORPTION FROM THE ALIMENTARY CANAL
The invention dissolves the problem of the pharmaceutical preparation being a factor stimulating the absorption of microelements. The essence of the invention is that the preparation contains...
|
|
|
US20090233872 |
Therapeutic Agent for Neurodegenerative Disease
[Problems] To provide a neuronal cell death inhibitor and a therapeutic agent for a neurodegenerative disease, particularly Parkinson's disease. [Means for Solving Problems] It is known that DJ-1...
|
|
|
US20090233871 |
Complexed polypeptide and adjuvant for improved vaccines
Immunogenic polypeptides having the capability to precipitate and focus a CpG adjuvant exhibit enhanced in vivo priming of a cytotoxic T-lymphocyte (CTL) response. Accordingly, compositions that...
|
|
|
US20090232866 |
Oligopeptides as coating material for medical products
The present invention relates to a pharmaceutical composition comprising a caspase inhibitor and/or a compound of the general formula R-Lys-X, methods for coating medical products using said...
|
|
|
US20090232821 |
Use Of A Growth-Stimulating Protein
This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or...
|
|
|
US20090227521 |
USE OF COMPOUNDS IN THE TREATMENT OF ISCHEMIA AND NEURODEGENERATION
TPP II (tripeptidyl peptidase II) inhibitors are useful in the treatment of a neurodegenerative disease, for example Alzheimer's, Parkinson's or Huntingdon's disease or an ischemic condition, for...
|
|
|
US20090227520 |
Treatment methods using peptides related to amyloid precursor protein
The invention provides a compound having formula X 1 -Arg-Xaa-Arg-X 2 in which X 1 and X 2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the...
|
|
|
US20090227505 |
Methods and uses for protein breakdown products
Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of...
|
|
|
US20090227491 |
ANTIVIRAL PHOSPHINATE COMPOUNDS
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to...
|
|
|
US20090221514 |
METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY
The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or...
|
|
|
US20090221513 |
Treatment of Neurodegenerative Disorders
Peptides having the sequence D-Arg-L-Glu-L-Arg, or the sequence L-Arg-D-Glu-L-Arg and derivatives thereof, are disclosed. Such peptides are useful in treatment of neurodegenerative disorders, and...
|
|
|
US20090221505 |
COMPOSITIONS AND METHODS RELATED TO SYNCHRONOUS SELECTION OF HOMING PEPTIDES FOR MULTIPLE TISSUES BY IN VIVO PHAGE DISPLAY
Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct...
|
|
|
US20090221482 |
TISSUE PROTECTIVE PEPTIDES AND USES THEREOF
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present...
|
|
|
US20090220505 |
METHODS OF INHIBITING AMYLOID TOXICITY
The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic...
|
|
|
US20090220463 |
Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide
Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins.
|
|
|
US20090215703 |
PAR-2 Agonist
The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the...
|
|
|
US20090215702 |
Uv-Induced Dermatitis Inhibitor and Atopic Dermatitis Inhibitor
At least one substance selected from the group consisting of a water-soluble peptide comprising at least one unit selected from the group consisting of an isoleucylglycylseryl unit, a...
|
|
|
US20090214575 |
Annexin II and uses thereof
The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for...
|